Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
21st Century Oncology
Scottsdale, Arizona, United States
Tower Urology / Tower Research Institute
Los Angeles, California, United States
Prostate Oncology Specialists, Inc.
Marina del Rey, California, United States
The Urology Center of Colorado
Denver, Colorado, United States
Howard University Cancer Center
Washington D.C., District of Columbia, United States
First Urology, PSC
Jeffersonville, Indiana, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Tulane University
New Orleans, Louisiana, United States
Highland Clinic
Shreveport, Louisiana, United States
Chesapeake Urology Research Associates
Towson, Maryland, United States
Start Date
October 1, 2012
Primary Completion Date
July 1, 2017
Completion Date
July 1, 2017
Last Updated
August 19, 2019
139
ACTUAL participants
Sipuleucel-T
BIOLOGICAL
Lead Sponsor
Dendreon
NCT06842498
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04550494